SYK and uterine corpus sarcoma: We tested the ability of R406 to modulate taxane resistance in another MDR model, the doxorubicin-selected human uterine sarcoma variant MES-SA/Dx5, which expresses higher levels of transporter than SK-OV-3/TR (8-fold) and is negative for Syk expression (Fig 1A).